Kornimate/medical-research-clean huggingface dataset:
investigation of myocardial protection level with specific cardioplegia methods in cardiac surgery

Conditions: Bypass Complication; Cardioplegia Solution Adverse Reaction; Endothelial Degeneration; Oxidative Stress; Aortic Valve Stenosis; Coronary Artery Disease

Summary: investigating the myocardial effects of cold blood cardioplegia and del nido cardioplegia solution, which are routinely used in clinical practice, will contribute to the studies in the literature on the safety and efficacy of these two methods. for this purpose, patients with coronary artery disease that going to be coronary artery bypass graft (cabg) surgery will be classified within the scope of the syntax score, the level of exposure to cardioplegia change in proportion to their score will be examined. also, left ventricular muscle mass will be calculated in patients who will undergo aortic valve replacement (avr) due to aortic stenosis, and myocardial protection level proportional to muscle mass will be examined, and cardioplegia efficiency will be compared.

endocan, e-selectin, tnf(tumor necrosis factor)-alpha, total oxidant and antioxidant status will be studied on sequential blood samples taken from patients who will undergo elective coronary artery bypass grafting operation and aortic valve replacement, via retrograde cardioplegia cannula before induction, at the beginning of cardiopulmonary bypass and after removing the cross-clamp. with routinely used parameters like hemogram, lactate, liver and kidney function tests morbidity-mortality rates for specific cardioplegia technique will be compared

Eligibility criteria:
inclusion criteria: * subjects planned to have elective coronary artery bypass grafting for coronary artery disease * subjects planned to have elective aortic valve surgery due to aortic valve stenosis * patients aged 18-75 years * bmi of 18.5-30 * diabetic and non-diabetic patients * smokers and non-smokers exclusion criteria: * subjects under 18 years old * subjects older than 75 years * patients requiring valve surgery with coronary artery bypass * patients requiring aortic valve surgery with pathologies other than aortic valve stenosis * patients requiring mitral or tricuspid valve surgery * patients undergoing emergency coronary bypass * bmi \> 30 obese patients

Keywords: coronary artery bypass grafting cardioplegia cardiopulmonary bypass aortic valve replacement endothelial damage oxidative stress
dual injection espb versus single injection espb for laparotomies

Conditions: Post Operative Pain; Regional Block

Summary: to evaluate and compare the efficacy of single level injection erector spinae plane block versus double level injection erector spinae plane block in laparotomies


Eligibility criteria:
inclusion criteria: 1. age18-60. 2. both genders. 3. abdominal surgery. 4. asa i-iii. exclusion criteria: 1. drug allergy. 2. morbid obesity (bmi \>40 kg/m2). 3. psychiatric disorder. 4. opiod dependence. 5. patient refuse.

Keywords: espb pain regional block
prevention of umbilical port-site hernia after laparoscopic cholecystectomy using a prosthetic mesh versus simple suture

Conditions: Port-site Hernia

Summary: the incidence of port-site hernia in patients with risk factors (obesity, elderly, diabetes and lung disorders) can be reduced by the use of a prophylactic mesh in the closure of umbilical port site.


Eligibility criteria:
inclusion criteria: * age \> 65 years * bmi \> 30 kg/m2 * diabetes mellitus * lung disease * elective laparoscopic cholecystectomy exclusion criteria: * umbilical hernia * previous laparotomy * conversion to open procedure * loss during the follow up
psychological impact of covid-19 on intensive care survivors

Conditions: COVID-19; Psychological Distress; Depression; Anxiety; Post-traumatic Stress Disorder; Post Intensive Care Syndrome

Summary: psychological distress is commonly experienced by survivors of an intensive care admission, including patients treated during previous pandemics. whilst data emerges about the short-term impact of covid-19 on patients and healthcare systems, the long term impact remains unclear. the purpose of this trainee-led, multi-centre longitudinal study is to assess the short- and long-term psychological impact on patients who have survived an admission to intensive care due to covid-19, and identify possible predictors of anxiety, depression and trauma symptoms in this patient group.

the primary objective is to identify the proportion of patients surviving an admission to intensive care due to covid-19 who experience anxiety, depression and/or trauma symptoms in the 6 months post discharge. whilst the secondary objectives are to identify demographic, clinical, physical and/or psychosocial predictors of depression, anxiety and/or trauma symptoms at 3-, 6- and 12-months post discharge from icu. and to assess the feasibility of using a self-reported online questionnaire to assess anxiety, depression and/or trauma symptoms in patients following icu admission. an amendment was approved by the east midlands - derby research ethics committee on 17 march 2022, to conduct three sub-studies: 1. semi-structured interviews - to explore the experiences of critical care survivors following covid-19 infection during their recovery phase, including perceptions about the care received and support available to them. 2. survey of follow-up services offered to icu survivors - to assess geographical differences in the availability and structure of follow-up services offered to patients with critical covid-19 after hospital discharge. 3. survey of study team members - to gain feedback from the study team members on their involvement in the study.

Eligibility criteria:
inclusion criteria: * adult patients ≥18 years * survival to intensive care / high dependency unit discharge following an admission of ≥24 hours * treated for covid-19 exclusion criteria: * unable to complete questionnaires * unable or unwilling to consent * unable to speak, understand or communicate in english * patients with diagnosed, pre-existing cognitive impairment (at the time of icu admission) * patients without a fixed abode, at which postal questionnaires might be received, and who have no access to a personal email address.
ranolazine sr in patients with chronic angina who remain symptomatic despite maximal treatment with amlodipine

Conditions: Angina

Summary: the study will be a multi-national, double-blind, randomized, placebo-controlled, parallel group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in approximately 500 patients with chronic angina who remain symptomatic despite daily treatment with the maximum labeled dose of amlodipine (10 mg daily), a calcium channel blocker approved for the treatment of chronic angina. eligible patients will be randomized to receive ranolazine 1000 mg or placebo twice daily, in addition to a daily dose of 10 mg of amlodipine. participation in the study will last approximately 3 months.


Eligibility criteria:
eligible patients must have a diagnosis of chronic angina, with documented evidence of coronary artery disease or prior myocardial infarction, in addition to other study entry criteria. prior to entering the study, patients will be required to have had at least two weeks of treatment with amlodipine 10 mg daily, with the discontinuation of all other anti-anginal therapy for the duration of the study.

Keywords: angina chest pain coronary artery disease heart disease
efficacy of a single injection of ctm for post-operative cmc arthritis

Conditions: Osteoarthritis; Osteoarthritis Thumb Base Joint; Carpometacarpal Osteoarthritis; Thumb

Summary: the goal of this study is to determine the success rate of a single carpometacarpal (cmc) thumb injection after arthroplasty surgery for primary osteoarthritis of the cmc joint.

ctm biomedical markets and distributes decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. these are structural tissue allografts processed according to the criteria contained in 21cfr 1271.10(a) for regulation solely under section 361 of the public health service act. ctm flow is decellularized particulate human placental connective-tissue matrix provided in a vial. postoperative pain after basilar thumb arthritis reconstruction is often quite significant. ctm flow is an extracellular matrix implant that supplements and replaces damaged tissues. small unpublished case series in total knee arthroplasty, ent procedures, and rotator cuff repair have shown beneficial results from ctm. we hope to show similar results in this assessment of ctm in the post-operative cmc arthroplasty patient population. the primary outcome measure will be narcotic use postoperatively in the first 3 weeks after surgery, as measured by patient tracking. patients will track post-op pain meds including narcotics, and otc pain medication for the duration of their follow up period. per standard of care, patients will be encouraged to change to tylenol and/or ibuprofen pain medicine as soon as they are able. secondary outcomes will be quickdash and vas pain.

Eligibility criteria:
inclusion criteria: 1. males or females age 18 or older 2. patients presenting for basilar thumb reconstruction surgery (any surgical technique) 3. patients who can consent to be a part of this study 4. patients who are able to return to the indiana hand to shoulder center or satellite location for follow up time points exclusion criteria: 1. additional procedures at the same time 2. patients with previous basilar thumb reconstruction on the operative side (revision surgery) 3. chronic narcotic use 4. women who are pregnancy or breastfeeding 5. non-english speaking
comparative evaluation of the performance of different thromboplastin reagents on prothrombin time and factorial assays in situations of isolated extrinsic pathway factor deficiency or liver damage.

Conditions: Hemorrhagic Disorders; Extrinsic Pathway Factor Deficiency; Hepatocellular Insufficiency With Coagulopathy

Summary: primary purpose : compare the sensitivity of several thromboplastin reagents of various origins to prothrombin time and factor ii, v, vii and x assays in two different populations of patients : * patients with an isolated extrinsic pathway deficiency (acquired or congenital) of factor ii or v or vii or x. * patients with an hepatocellular insufficiency generally associated with coagulopathy (with an intensity proportional to the degree of hepatic impairment). results of this work should improve knowledge of sensitivity of the screening test represented by the prothrombin time, depending on the origin of thromboplastin reagent used, in relation with coagulopathies mentioned above, as well as the performance of factors ii, v, vii, x assays. this work would help to choice of the most suitable reagent for the needs of each hemostasis laboratory/center.


Eligibility criteria:
inclusion criteria : * plasma samples from patients addressed to the laboratory of the strasbourg university hospital (strasbourg france) collected and anonymized after completion of the routine testing. * patient with an isolated or combined extrinsic pathway factor deficiency (factor ii, v, vii, x). exclusion criteria : * patient treated with an oral anticoagulant treatment. * patient treated with a parenteral anticoagulant treatment (apart from therapeutic dosages of unfractionated heparin and low molecular weight heparin).

Keywords: thromboplastin sensitivity prothrombin time
open clinical study, comparing non-inferiority of chronic plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the purpose of this study is: to evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis. - population: 50 patients will be selected from both sexes, healthy, between 18 and 65 years with a clinical diagnosis of chronic plaque psoriasis with pasi \<20%, according to the criteria of inclusion and exclusion.


Eligibility criteria:
inclusion criteria: * age range: between 18 and 65 * a patient with chronic plaque psoriasis * pasi \<20% * presence of bilateral lesions with at least 2 cm in diameter and each with some degree of symmetry * levels of serum calcium and phosphorus within the normal range of reference or in case of changes, classified as irrelevant by the investigator * in the case of female patients, agreement or maintenance of safe use of contraception such as barrier (condom, diaphragm), hormonal contraceptives (pills, implants or injections), iuds, or abstinence (no sex) * reading, understanding, agreement and signature of the patient in the term of consent. exclusion criteria: * gestation (confirmed by urine test indicator) * lactation * history of hypersensitivity to components of medicines * psoriasis with different clinical presentation of the plates * clinical picture of psoriasis involving only the scalp, face, groin, armpit and / or other intertriginous area * patient requires the use of concomitant medication (topical or systemic) that may alter the course of the disease during the study period * use of any systemic treatment for psoriasis within 12 weeks before the start of the study * use of systemic corticosteroids within 28 days before the start of the study * use of topical corticosteroids or other topical therapies in the areas of assessment within 02 weeks before the start of the study * use of phototherapy (uvb / uva-p) within 04 weeks before the start of the study * patients who have participated in another clinical study within 30 days before the start of the study * use of any medication or possession of any disease which, in the opinion of the investigator might interfere with the performance or interpretation of the study * laboratory tests changed (serum ast and alt, alkaline phosphatase, urea and creatinine, total bilirubin and fractions) * patients with demonstrated hypercalcemia or evidence of toxicity of vitamin d * other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation

Keywords: chronic plaque psoriasis to evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis
psychosocial support for acute hospital pain and distress

Conditions: Acute Pain

Summary: the purpose of this randomized study is to determine the impact of three different types of psychosocial support delivered by social workers to patients reporting uncontrolled pain during a hospital stay. this study will examine the differential effects of brief mindfulness training, therapeutic suggestion, and psychoeducation for patients reporting uncontrolled pain.


Eligibility criteria:
inclusion criteria: * english-speaking males or females 18 or older within the university of utah hospital system reporting "intolerable pain" or "inadequate pain control" on the clinically aligned pain assessment tool (capa; donaldson \& chapman, 2013). exclusion criteria: * altered mental status due to delirium, psychosis, or pharmacological sedation as determined by clinical assessment.
acute effects of a heat-not-burn tobacco product on pulmonary function in healthy non smokers.

Conditions: Heated Tobacco; Respiratory Function; Tobacco Toxicity

Summary: iqos ("i-quit-ordinary-smoking,") is a type of "heat-not-burn" (hnb) tobacco product. there is evidence of a growing number of young people who try iqos as a 'safe' alternative of cigarette. the effect of the acute exposure to iqos smoke on pulmonary function of healthy non smokers has not been studied extensively. objectives: evaluation of the acute effects of iqos on pulmonary function,exhaled co, o2 saturation, arterial pressure and heart rate. methods: healthy non smokers, underwent exhaled co measurement, spirometry including flows, volumes and diffusion capacity, and measurement of their respiratory resistances at 5, 10 and 20 hz (r5hz, r10hz and r20hz) with the use of an impulse oscillometry system (ios) before and after the use of an iqos. additionally heart rate and arterial blood pressure were also measured.

all participants underwent pulmonary function tests (pft) (masterscreen pft, jaeger, wurzburg, germany) and total respiratory resistances measurement with an impulse oscillometry system (ios)( (viasys jaeger masterscreen ios system).from the basic pulmonary measurements (flows and dynamic lung volumes), forced expiratory volume in 1 second (fev1), forced vital capacity (fvc), tiffenau index (fev1/fvc, fev1%), peak expiratory flow (pef), maximal expiratory flow (mef) at 25%, 50%, and 75% of vital capacity, functional residual capacity (frc), total lung capacity (tlc), residual volume (rv), diffusion capacity (dlco) were measured. each manoeuvre was repeated for at least three technically acceptable forced expiratory flow curves in order to attain the best results. respiratory impedance at 5 hz (z5hz) and respiratory resistance at 5, 10, and 20 hz (r5hz, r10hz, and r20hz, respectively), reactance at 5, 10, and 20 hz and resonant frequency were assessed with ios. heart rate, saturation of o2 (oxymetry) and arterial blood pressure were also measured. exhaled co measurement (pico smokerlyzer,bedfont scientific ltd, kent, u.k.) was performed after smoking heated tobacco (iqos): 5 minutes after smoking iqos , they repeated again pfts, ios, exhaled co heart rate, saturation of o2 (oximetry) and arterial blood pressure measurements.

Eligibility criteria:
inclusion criteria: 1. healthy male non smokers, 2. age 18-55 years 3. receiving no medications 4. no co morbidity - exclusion criteria: 1. aged \<18 years 2. smokers or ex-smokers 3. receiving any medications 4. any co morbidity -

Keywords: pulmonary function heated tobacco iqos
dexmedetomidine for the treatment of delirium after heart surgery

Conditions: Postoperative; Delirium; Psychomotor; Confusion

Summary: primary hypothesis: dexmedetomidine is equal or superior to haloperidol and placebo in the treatment of psychomotor confusion in patients who are recovering from heart surgery. study design: multi-centre, prospective, randomised, placebo-controlled double-blind study of dexmedetomidine vs. haloperidol for treatment of psychomotor confusion after cardiac surgery. data will be analyzed in two steps: the primary comparison is between placebo and dexmedetomidine. if the effect of dexmedetomidine is significant, a secondary comparison between dexmedetomidine and haloperidol will follow.


Eligibility criteria:
inclusion criteria: * age \> 65 years * clinical need for treatment of psychomotor confusion unresponsive to standard analgesic medication (rass +2 to +3) * heart surgery and extracorporeal circulation (ecc) within 7 days * written informed consent obtained before surgery * mentally competent at the time of written informed consent exclusion criteria: * ongoing neuroleptic, propofol and α2 agonist medication * intubated patient * uncompensated acute circulatory failure at time of randomisation (severe hypotension with mean arterial pressure \< 55 mmhg despite volume, vasopressors and iabp) * severe bradycardia without pacemaker backup (heart rate \< 50 beats/min) * av-conduction block ii-iii (without pacemaker backup) * severe hepatic impairment (serum bilirubin \> 101 µmol/l) * lithium therapy

Keywords: dexmedetomidine
evaluation of the performance and safety of a medical device developed to improve the reading of dyslexic patients

Conditions: Dyslexia

Summary: the aim of this study is to evaluate the efficacy and safety of a new medical device on the improvement of reading skills of dyslexic patients.

dyslexia is defined as a specific learning disability that is characterized by reading difficulties, in the absence of intellectual disability, neurological or psychiatric disorder, uncorrected sensory disturbance (sight, hearing) or an educational deficiency. dyslexia appears in the child from the earliest stages of learning in the form of a difficulty in mastering the learning of reading. this disorder is manifested by a generally hesitant reading, slowed down, full of errors, requiring a lot of effort for the child and may impact his reading comprehension. the dyslexia-related deficiency is of variable intensity depending on the individual; it may be accompanied by calculus disorders (dyscalculia), oral language (dysphasia), motor coordination (dyspraxia) or attention disorders with or without hyperactivity. in nearly 40% of cases, a child affected by dys disorders presents several learning disorders. to date, the causes of dyslexia are not yet clearly established. the wide variety of symptoms and disorders associated with dyslexia does not facilitate the identification of precise neurobiological / psycho cognitive mechanisms. there are therefore several theories: phonological, visual, temporal, cerebellar or proprioceptive auditory processing. recently, following work published in 2017, an anatomical cause based on maxwell's spots could also be a cause of dyslexia. the aim of this study is to evaluate a new medical device to compensate this probable anatomical cause.

Eligibility criteria:
inclusion criteria: * schooled in ce2, cm1 or cm2, * french mother tongue, * for whom developmental dyslexia has been diagnosed by a health professional who specializes in this learning disorder, * presenting an iq ≥ 80 and ≤130 according to the wisc-v test performed by a psychologist, * for which a written consent was obtained regarding his study participation. exclusion criteria: * with medical history or presenting a neurological pathology, * presenting a developmental disorder (autism, adhd, ...), * presenting hearing disorders, * presenting visual disorders, * any other condition that, in the opinion of health professionals, could impair its ability to complete the study or could pose a significant risk.

Keywords: dyslexia reading disorder
the relationship between scar formation and esd depth in therapy for gastric carcinoma

Conditions: Early Gastric Cancer; Endoscopic Submucosal Dissection

Summary: this study is a single-center, prospective, group-controlled clinical trial, aiming to clarify the relationship between the depth of dissection and scar formation in the treatment of early gastric cancer by esd, and to provide high-quality evidence-based medicine for the treatment of early gastric cancer.

this project intends to compare the scar size of esd for early gastric cancer with different peeling depths, explore the relationship between esd peeling depth, scar formation and gastric function, and clarify the differential impact of different peeling depths on the prognosis of patients. we plan to provide evidence for guidelines of early gastric cancer esd treatment based on the related data. in further, the project show insight into a more effective clinical technique which profit patients better prognosis.

Eligibility criteria:
inclusion criteria: * patients older than 18 years old and younger than 75 years old. * early gastric cancer (t1a stage) diagnosed by gastroscopy or ultrasonography, differentiated and no ulcer; or early gastric cancer (t1a stage), differentiated with ulcer, lesion diameter \<3cm; or early gastric cancer (t1a stage), undifferentiated and no ulcer, lesion diameter \<2cm. * pathological diagnosis of gastric cancer. * no further treatment is required. * patients diagnosed for the first time without other serious gastrointestinal diseases. exclusion criteria: * those who did not comply with the test requirements, obviously violated this protocol, or switched to other protocols in the middle of treatment. * advanced gastric cancer; or undifferentiated gastric cancer lesions \> 2 cm in diameter; or differentiated gastric cancer with ulcer lesions \> 3 cm in diameter. * coagulation disorders. * serious heart, liver, kidney and other diseases, can not tolerate esd treatment. * patients with gastric cancer complications such as gastrointestinal bleeding and perforation that need emergency treatment. * patients with distant metastasis. * patients with other tumors, patients with a history of malignant tumors (except early carcinoma in situ. * the patient himself requests to withdraw from the trial. * the researcher believes that the patient is not suitable to participate in this study.